Form 4: Omnicell Director Robin Seim Receives Equity Grant as Board Compensation

Omnicell, Inc. Director Robin Gene Seim was granted 6,828 restricted shares of common stock as part of the company's equity incentive plan for board member services.

Summary

• Robin Gene Seim, a Director of Omnicell, Inc. (OMCL), acquired 6,828 shares of common stock on June 1, 2025.
• These shares were granted as restricted stock under the Issuer's equity incentive plan, specifically for services as a Board Member, pursuant to the company's Board of Directors Compensation Plan.
• The shares were acquired at a price of $0, indicating a grant rather than a purchase.
• Following this transaction, Robin Gene Seim beneficially owns a total of 47,353 shares of Omnicell common stock.
• The granted shares are set to vest in full on the one-year anniversary of the grant date.

Sentiment

Score: 6

Explanation: The grant of restricted shares to a director is a standard compensation practice, aligning interests with shareholders. It's a neutral to slightly positive event, indicating ongoing board service and commitment, without significant financial implications for the company's immediate operations or capital structure.

Positives

• The grant of restricted shares aligns the interests of Director Robin Gene Seim with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• This transaction is part of a structured Board of Directors Compensation Plan, indicating a standard and transparent approach to executive and board remuneration.

Negatives

• The grant of new shares could result in minor dilution for existing shareholders, although the amount (6,828 shares) is relatively small in the context of a publicly traded company.

Future Outlook

The document indicates that the granted shares will vest in full on the one-year anniversary of the grant date (June 1, 2026), which is a future event related to the compensation structure.

Industry Context

Equity grants to board members are a common practice across industries, particularly in technology and healthcare sectors like Omnicell's, to align leadership incentives with long-term company performance and shareholder value creation.

Comparison to Industry Standards

• The practice of compensating board members with equity, such as restricted stock units, is a standard corporate governance practice across publicly traded companies, including peers in the healthcare technology sector like Cerner (now Oracle Health) or Allscripts (now Veradigm).
• The specific amount of the grant (6,828 shares) would typically be benchmarked against compensation packages for non-executive directors at companies of similar market capitalization and industry, ensuring competitive and appropriate remuneration for board service.

Corporate Governance

Related Party Transactions

• The grant of restricted shares to Robin Gene Seim, a Director of Omnicell, constitutes a related party transaction, as it involves compensation provided by the company to a member of its Board of Directors.

Stakeholder Impact

• Shareholders: The transaction aligns the director's interests with shareholders through equity ownership, potentially encouraging long-term value creation. There is a minor dilutive effect from the issuance of new shares.

Next Steps

• The granted shares will vest in full on the one-year anniversary of the grant date (June 1, 2026).

Key Dates

Keywords

Omnicell, OMCL, Form 4, SEC filing, Insider transaction, Restricted stock, Equity grant, Director compensation, Board of Directors, Share ownership, Corporate governance